tbuckley/cabot-search huggingface dataset:
"FALL OF BLOOD PRESSURE AFTER INJECTIONS OF NEO-ARSPHENAMIN"
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Brain Tumors In Children Exposed to Barbiturates: Reply
Authors: Ellen B. Gold, Ph.D., Leon Cordis, M.D., Dr.P.H., James A. Tonascia, Ph.D., Moyses Szklo, M.D., Dr.P.H.
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article Brain Tumors In Children Exposed to Barbiturates: Reply Get access Ellen B. Gold, Ph.D., Ellen B. Gold, Ph.D. Departments of Epidemiology and Biostatistics School of Hygiene and Public Health The Johns Hopkins University , 615 North Wolfe Street Baltimore, Maryland 21207 Search for other works by this author on: Oxford Academic PubMed Google Scholar Leon Cordis, M.D., Dr.P.H., Leon Cordis, M.D., Dr.P.H. Departments of Epidemiology and Biostatistics School of Hygiene and Public Health The Johns Hopkins University , 615 North Wolfe Street Baltimore, Maryland 21207 Search for other works by this author on: Oxford Academic PubMed Google Scholar James A. Tonascia, Ph.D., James A. Tonascia, Ph.D. Departments of Epidemiology and Biostatistics School of Hygiene and Public Health The Johns Hopkins University , 615 North Wolfe Street Baltimore, Maryland 21207 Search for other works by this author on: Oxford Academic PubMed Google Scholar Moyses Szklo, M.D., Dr.P.H. Moyses Szklo, M.D., Dr.P.H. Departments of Epidemiology and Biostatistics School of Hygiene and Public Health The Johns Hopkins University , 615 North Wolfe Street Baltimore, Maryland 21207 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 63, Issue 1, July 1979, Pages 3–4, https://doi.org/10.1093/jnci/63.1.3-a Published: 01 July 1979
Leads from the MMWR. Chronic disease control activities of medical and dental organizations
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cockroach Allergen Reduction by Extermination Alone in Low-Income, Urban Homes-A Randomized Control Trial
Authors: M. Sever, S.J. Arbes, J.C. Gore, R.G. Santangelo, B. Vaughn, H. Mitchell, C. Schal, D.C. Zeldin
Journal: Journal of Allergy and Clinical Immunology (2006)
Reversible ischemic colitis after intravenous vasopressin therapy
Authors: M. Lambert
Journal: JAMA (1982)

VASOPRESSIN reduces splanchnic blood flow, decreases portal pressure, and has been used in the treatment of bleeding esophageal varices.<sup>1</sup>Severe complications may arise from its use, in particular, myocardial and small-bowel ischemia.<sup>2</sup>We recently observed reversible ischemic colitis in a patient who received intravenous (IV) vasopressin for variceal hemorrhage. <h3>Report of a Case</h3> A 54-year-old man with alcoholic cirrhosis was admitted to the Hôpital Cantonal of Geneva because of hematemesis. There was no history of angina, claudication, or hypertension. The patient was conscious and oriented, with a pulse rate of 80 beats per minute and a blood pressure of 120/70 mm Hg. Hepatosplenomegaly was present without ascites. Bowel sounds were normal. Initial laboratory values included the following: hematocrit, 35%; leukocytes, 7,200/cu mm; platelets, 59,000/cu mm; prothrombin time, 14.2 s (control, 12 s); BUN, 18 mg/dL; sodium, 138 mEq/L; potassium, 4.3 mEq/L; chloride, 104 mEq/L; total serum bilirubin, 2.9
Leads from the MMWR. Premature mortality from diabetes mellitus--use of sentinel health event surveillance to assess causes
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of daily student performance
Authors: J. P. Colmore
Journal: JAMA (1966)

During the years 1952 to 1961, the Department of Medicine's Outpatient Teaching Clinic at the University of Oklahoma Medical Center undertook an evaluation of student performance. The structure both of the curriculum and of the outpatient clinic itself should be enlarged upon in order to provide an understanding of the setting in which this evaluation took place. Just prior to this era, the general screening clinic and the Internal Medicine Clinic and its various subspecialty clinics were amalgamated into a single clinic known as the Medicine Clinic. Almost without exception, new ambulatory adult patients were sent to this clinic. (Otherwise healthy prenatal patients constituted the largest group of patients not routinely seen first in the Medicine Clinic.) These patients were subjected to a detailed history and physical examination by the senior medical students assigned to the clinic and the findings were then reviewed and discussed with a member of the
Abstract 296: Bone Marrow Derived Cells Contribute to Cell Turnover in Ageing Murine Hearts
Authors: Helge Möllmann, Holger M Nef, Christian Troidl, Sandra Voss, Mathias Heil, Sawa Kostin, Michael Weber, Christian W Hamm, Albrecht Elsässer
Journal: Circulation (2007)

Background: The paradigm that the heart is a terminally differentiated organ has recently been challenged since some studies reported the ability of bone marrow (BM) derived cells to transdifferentiate into cardiomyocytes after myocardial damage. However, the physiological role of bone marrow derived cells during the lifespan of an undamaged heart is widely unknown. We therefore examined the quantity and phenotype of bone marrow derived cells in aged murine hearts. Methods: 12-week-old mice (n=20) were sublethally irradiated and BM from enhanced green fluorescent-transgenic (eGFP) littermates was transplanted. After 1 month 5 mice were sacrificed and served as control. The remaining mice were sacrificed after 18.2±1.1 months. Immunohistochemistry was performed in 10 hearts using titin antibodies to identify cardiomyocytes, vimentin for fibroblasts, sMemb for myofibroblasts, α-smooth muscle actin for smooth muscle cells, F4/80 for macrophages, BS-1 and CD31 for endothelial cells. Additionally, anti-eGFP immunostaining was used to exclude autofluorescence. Sections were analyzed using fluorescence and confocal laser microscopy. The remaining 5 hearts were digested with collagenase and cell sorting was performed for a quantification of BM-derived cells in relation to eGFP negative cells. Results: BM transplantation was successful as FACS analysis showed 92±5% eGFP expressing leukocytes after 1 month and 78±6% after 18 months. In the juvenile hearts only few eGFP-positive cells were detected (&lt;1 cell/mm2). Numerous eGFP-positive cells were found in left ventricular sections in the old hearts. Histological quantification revealed 9.3±3.3 cells/mm2 to be derived from BM cells. Most of these cells were fibroblasts and myofibroblasts. In addition, numerous endothelial cells and smooth muscle cells contributing to neoangiogenesis were detected. Few eGFP-positive cardiomyocytes could be identified. The cell sorting of eGFP-positive cells documented 4.8±1.9% of all cardiac cells to be derived of BM cells. Conclusion: The present study demonstrates for the first time a substantial recruitment and accumulation of BM derived cells in the ageing myocardium suggesting their contribution in cell turnover of the heart during the lifespan of mice.
RECURRENT BULLOUS ERUPTION OF THE FEET
Authors: E. A. COCKAYNE
Journal: British Journal of Dermatology (1938)

Journal Article RECURRENT BULLOUS ERUPTION OF THE FEET Get access E. A. COCKAYNE, D.M., F.R.C.P. E. A. COCKAYNE, D.M., F.R.C.P. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 50, Issue 7, 1 July 1938, Pages 358–362, https://doi.org/10.1111/j.1365-2133.1938.tb10576.x Published: 01 July 1938
Thalidomide Polyneuropathy
Authors: Sidney Cohen
Journal: New England Journal of Medicine (1962)

THALIDOMIDE (alpha-[N-phthalimido]-glutarimide)‡ is a hypnotic frequently prescribed in Europe.1 Investigations in this country are being conducted to evaluate its activity as a daytime sedative and for the treatment of insomnia.2 , 3 Advantages over the commercially available hypnotics are its nontoxicity in animal studies and the low incidence of side effects in the earlier foreign reports. Ayd4 suggests that its nonlethality may make it the hypnotic of choice for potentially suicidal, depressed patients.I have been able to confirm the very satisfactory sleep regulation with thalidomide.5 The case reported below had been a diagnostic problem for months until a recent letter to . . .
Combined Action of Penicillin G with Methicillin or Oxacillin Against Staphylococcus Aureus
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Physician's Hamlet
Authors: John F. Burnum
Journal: Annals of Internal Medicine (1997)

Letters15 October 1997A Physician's HamletJohn F. Burnum, MDJohn F. Burnum, MDTuscaloosa, AL 35401Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00035 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Gonnella and I agree that Hamlet's long agonizing delay in acting against Claudius for the suspected murder of Hamlet's father is justified. As a youthful university student, Hamlet resents having to take on the burden of revenge. The risks involved in confronting the divine authority of a king are awesome, and in killing Claudius out of hate and for self-serving ambition, Hamlet himself would be damned. Furthermore-and here I differ with Gonnella's claim that the regicide is “unambiguously clear”-Hamlet delays because he is unsure of Claudius's guilt. Only we, the audience, ever know that Claudius is guilty; ... Author, Article, and Disclosure InformationAuthors: John F. Burnum, MDAffiliations: Tuscaloosa, AL 35401 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 October 1997Volume 127, Issue 8_Part_1Page: 658 ePublished: 15 August 2000 Issue Published: 15 October 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group
Authors: A. S. Goldie
Journal: JAMA (1995)

<h3>Objective.</h3> —To assess the value of measuring circulating concentrations of mediators (endotoxin, tumor necrosis factor-α [TNF-α], interleukin-1β [IL-1β], and interleukin-6 [IL-6]) and their endogenous antagonists (antiendotoxin core antibody [EndoCAb], interleukin-1 receptor antagonist [IL-1ra], and soluble TNF receptors [sTNF-R]) in predicting mortality and organ failure in sepsis syndrome. <h3>Design.</h3> —Cohort study with a follow-up period of 30 days. <h3>Setting.</h3> —Intensive therapy units of five tertiary referral centers in Scotland. <h3>Subjects.</h3> —A total of 146 intensive therapy unit patients with sepsis syndrome underwent repeated sampling during a 10-day period following admission to an intensive therapy unit. <h3>Main Outcome Measures.</h3> —Circulating concentrations of mediators and antagonists were compared in survivors and nonsurvivors. <h3>Results.</h3> —Median Acute Physiology and Chronic Health Evaluation II score was 23 (range, 8 to 40). Mortality at 30 days was 49%. On entry to the study, circulating endotoxin was detected in 66% of patients, TNF-α in 14%, and IL-1β in 29%. Levels did not predict mortality or organ failure. Patients with IL-6 concentrations in excess of 3000 pg/mL had an increased mortality rate (64% vs 40%,<i>P</i>=.02). The incidence of IgG EndoCAb depletion on entry to the study was 26% in nonsurvivors and 10% in survivors (<i>P</i>=.02). Initial concentrations of both type I and type II sTNF-R were significantly higher in nonsurvivors (<i>P</i>&lt;.01). Initial circulating IL-1ra concentrations were not of value in predicting mortality. Cytokine antagonists were present in concentrations 30- to 100 000-fold greater than their corresponding cytokine. <h3>Conclusion.</h3> —The observed high circulating levels of the cytokine antagonists IL-1ra and sTNF-R and the relatively small proportion of patients developing EndoCAb depletion may contribute to the limitations of therapies that aim to augment natural defenses against endotoxin or the proinflammatory cytokines. (<i>JAMA</i>. 1995;274:172-177)
The St. Louis Medical Society.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Women's Science
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hazards of oral anticoagulants during pregnancy
Authors: R. E. Stevenson
Journal: JAMA (1980)

Prenatal exposure to oral anticoagulants during pregnancy may result in defective fetal development or life-threatening hemorrhage. Fetal exposure during the first eight weeks of pregnancy may cause abnormal development of the facial structures, hypoplastic digits, stippled epiphyses, and mental retardation. Midtrimester exposure may result in optic atrophy, faulty brain growth, and developmental retardation. Third-trimester exposure may produce fetal anticoagulation, predisposing the infant to life-threatening hemorrhage in the perinatal period. Anticoagulation with heparin sodium does not provide a clearly safe alternative, since this therapy has been associated with excessive fetal loss. (<i>JAMA</i>243:1549-1551, 1980)
Genotype correlations with blood pressure and efficacy outcomes from the randomized phase III AXIS trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma.
Authors: Bernard J. Escudier, Brian I. Rini, Robert J. Motzer, Jamal Christo Tarazi, Sinil Kim, Xin Huang, Brad Rosbrook, Patricia A English, A Katrina Loomis, James Andrew Williams
Journal: Journal of Clinical Oncology (2014)

4528 Background: In the AXIS trial, axitinib significantly increased progression-free survival (PFS) vs sorafenib in patients with previously treated metastatic renal cell carcinoma (mRCC). Final analyses of association between select germline single nucleotide polymorphisms (SNPs) and outcomes in AXIS are reported. Methods: DNA samples from blood were genotyped by TaqMan allelic discrimination. Logistic/Cox regression analyses evaluated association between 15 SNPs in 4 genes (VEGF-A, VEGFR1, VEGFR2, HIF1α) and blood pressure (BP; grade ≥3 hypertension, diastolic BP >90 mmHg or increase ≥15 mmHg from baseline) and efficacy (overall survival [OS], independently-assessed objective response rate [ORR] and PFS) endpoints. Kaplan-Meier PFS/OS estimates were compared with 2-sided unstratified log-rank tests. Multivariate analyses assessed SNPs and baseline characteristics as potential predictors of PFS/OS. Results: Genotype samples were available for 305/714 (43%) patients: 159 received axitinib, 146 sorafenib. After Bonferroni correction for multiple comparisons, no association was found for SNPs with BP endpoints. In the axitinib arm, HIF1α rs11549465 (C/T vs C/C) was associated with shorter PFS (2.8 vs 8.3 mo; HR 1.93; Punadj=0.006; Padj=0.09) and OS (13.3 vs 22.6 mo; HR 1.88; Punadj=0.007; Padj=0.11), and VEGF-A rs699947 (A/A vs C/C) and rs833061 (C/C vs T/T) with longer OS (27.0 vs 13.4 mo; HR 0.39; Punadj=0.001; Padj=0.015). In the sorafenib arm, VEGFR2 rs2071559 (G/G vs A/A) was associated with higher ORR (21% vs 0%; Punadj=0.005; Padj=0.075), and longer PFS (4.7 vs 2.9 mo; HR 0.49; Punadj=0.01; Padj=0.15) and OS (26.8 vs 13.8 mo; HR 0.41; Punadj=0.002; Padj=0.03). In multivariate analyses, no SNP predicted axitinib efficacy; VEGFR2 rs2071559 predicted PFS (P=0.0053) and OS (P=0.0027) for sorafenib. Sensitivity/specificity of VEGFR2rs2071559 for OS was <80%. Conclusions: No SNP predicted axitinib outcomes, whereas VEGFR2 rs2071559 may have predicted sorafenib efficacy in patients with mRCC. Sensitivity/specificity limitations, however, preclude the use of this SNP for selecting sorafenib in individual patients. Clinical trial information: NCT00678392.